Press Releases SAB Biotherapeutics, Inc.

Equities

SABS

US78397T2024

Delayed Nasdaq Other stock markets 04:30:00 2024-05-08 pm EDT			5-day change	1st Jan Change
4.1 ^USD	+0.24%		0.00%	-40.36%

May. 06	SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors	CI
Apr. 16	SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors	May. 06	AQ
SAB Biotherapeutics Provides SAB-142 Trial Update	Apr. 16	AQ
SAB Biotherapeutics : Regulation FD Disclosure - Form 8-K	Apr. 15	PU
SAB Biotherapeutics to Present at INNODIA Annual Meeting	Apr. 08	AQ
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference	Apr. 04	AQ
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results	Apr. 01	AQ
SAB Biotherapeutics : Reports Full Year 2023 Operating and Financial Results March 29, 2024 - Form 8-K	Mar. 29	PU
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results	Mar. 29	AQ
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	Mar. 25	AQ
SAB Biotherapeutics to Present at the BIO CEO and Investor Conference	Feb. 26	AQ
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference	Feb. 23	AQ
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 09	AQ
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 08	AQ
SAB Biotherapeutics Announces Executive Leadership Change	Feb. 02	AQ
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement	Jan. 23	AQ
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split	Jan. 02	GL
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes	Nov. 30	AQ
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes	Nov. 29	AQ
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors	Nov. 20	GL
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes	Nov. 14	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases SAB Biotherapeutics, Inc.

Equities

SABS

US78397T2024

Press Releases

Filters